Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.

Amanda Jane Williams Gibson Haocheng Li Adrijana D'Silva Roxana Alina TudorAnifat A ElegbedeShannon Mary OtsukaD Gwyn Bebb Winson Y Cheung

Published in: Medical oncology (Northwood, London, England) (2018)

Number rather than location of EPMS is a prognostic factor in patients with stage IV M1b NSCLC. This information is relevant for accurate prognostication, stratification of participants in future clinical trials, and timely and appropriate advanced care planning.

Keyphrases

prognostic factors
clinical trial
small cell lung cancer
healthcare
palliative care
quality improvement
high resolution
advanced non small cell lung cancer
pain management
health information
phase ii
randomized controlled trial
free survival
affordable care act
open label
brain metastases